Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Merck becomes Arvinas' first partner for new PROTAC-based drugs

Executive Summary

Two-year old Arvinas LLC penned its first major agreement, signing a multi-year deal with Merck & Co. Inc. to use the PROTAC protein degradation technology against targets selected by Merck. While Arvinas’ focus up until now has been using the platform for cancer, the companies note that several undisclosed therapy areas will be involved.

Deal Industry
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies